Rein M. S., A. J. Friedman et al. Cytogenetic abnormalities in uterine leiomyomata // Obstet. Gynecol. 1991. №77 (6). Р. 923–926.

Tiltman A. J. Smooth muscle neoplasms of the uterus//Curr. Opin. Obstet. Gynecol. 1991. №9 (1). Р. 48–51.

Kawaguchi K. S. Fujii et al. Mitotic activity in uterine leiomyomas during the menstrual cycle // Am. J. Obstet. Gynecol. 1989. № 160 (3). Р. 637–641.

Fujimoto J., Ichigo S. et al. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers // Cancer. Lett. 1998. №130 (1–2). Р. 115–120.

Friedman A. J. Clinical experience in the treatment of fibroids with leuprolide and other GnRH agonists //Obstet. Gynecol. Surv. 1989. №44 (5). Р. 311–313.

Hyder S. M., Huang J. C. et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins // Environ. Health Perspec. 2000. T. 108. Suppl. 5. Р. 785–790.

Shimomura Y., Matsuo H. et al. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma // J. Clin. Endocrinol. Metab. 1998. №83 (6). Р. 2192–2198.

Тихомиров А. Л. Миома, патогенетическое обоснование органосохраняющего лечения: монография. М., 2013.

Kelly R. W., King A. E., Critchley H. O. D. Inflammatory mediators and endometrial function – focus on the perivascular cell // Reprod. Immunol. 2002. №57. Р. 81–93.

Baird D. T., Brown A., Critchley H. O. D. et al. Effect of long-term treatment with low-dose mifepristone on the endometrium // Hum. Reprod. 2003. №18. Р. 61–68.

Eisinger S. H., Bonfiglio T., Fiscella K., Meldrum S., Guzick D. S. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas // J. Minim. Invasive Gynecol. 2005. №12. Р. 227–233.